Diabetic Ketoacidosis Secondary to New Onset Type 1 Diabetes Mellitus Related to Pembrolizumab Therapy.

Andrea Hernandez; Bassem Zeidan; Parth R Desai; Johnathan Frunzi

doi:10.7759/CUREUS.13302

Diabetic Ketoacidosis Secondary to New Onset Type 1 Diabetes Mellitus Related to Pembrolizumab Therapy.

Andrea Hernandez
, Bassem Zeidan
, Parth R Desai
, Johnathan Frunzi

HCA Florida Trinity Hospital

Internal Medicine, Medical Center of Trinity, Trinity, USA.

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Cureus
Volume	13
Issue number	2
DOIs	https://doi.org/10.7759/CUREUS.13302
State	Published - Feb 12 2021

Disciplines

Medicine and Health Sciences
Internal Medicine

Access to Document

10.7759/CUREUS.13302License: Unspecified

Cite this

@article{8f943115e0104af183afb900ca1b7084,

title = "Diabetic Ketoacidosis Secondary to New Onset Type 1 Diabetes Mellitus Related to Pembrolizumab Therapy.",

author = "Andrea Hernandez and Bassem Zeidan and Desai, \{Parth R\} and Johnathan Frunzi",

note = "Pembrolizumab is an immunoglobulin G4 (IgG4) monoclonal antibody used in the treatment of various types of cancers. Despite its efficacy, pembrolizumab does not specifically target cancer cells which often leads to common side effects seen in immunotherapies such as diarrhea, rash, fatigue, nausea, decreased appetite, pruritus, and endocrinopathies.",

year = "2021",

month = feb,

day = "12",

doi = "10.7759/CUREUS.13302",

language = "American English",

volume = "13",

journal = "Cureus",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Diabetic Ketoacidosis Secondary to New Onset Type 1 Diabetes Mellitus Related to Pembrolizumab Therapy.

AU - Hernandez, Andrea

AU - Zeidan, Bassem

AU - Desai, Parth R

AU - Frunzi, Johnathan

N1 - Pembrolizumab is an immunoglobulin G4 (IgG4) monoclonal antibody used in the treatment of various types of cancers. Despite its efficacy, pembrolizumab does not specifically target cancer cells which often leads to common side effects seen in immunotherapies such as diarrhea, rash, fatigue, nausea, decreased appetite, pruritus, and endocrinopathies.

PY - 2021/2/12

Y1 - 2021/2/12

UR - https://europepmc.org/article/PMC/PMC7957841

U2 - 10.7759/CUREUS.13302

DO - 10.7759/CUREUS.13302

M3 - Article

VL - 13

JO - Cureus

JF - Cureus

IS - 2

ER -

Diabetic Ketoacidosis Secondary to New Onset Type 1 Diabetes Mellitus Related to Pembrolizumab Therapy.

Disciplines

Access to Document

Other files and links

Cite this